Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 5;33(23):9592-600.
doi: 10.1523/JNEUROSCI.5610-12.2013.

MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration

Ashley S Harms  1 , Shuwen Cao, Amber L Rowse, Aaron D Thome, Xinru Li, Leandra R Mangieri, Randy Q Cron, John J Shacka, Chander Raman, David G Standaert
Affiliations

MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration

Ashley S Harms et al. J Neurosci. .

Abstract

Accumulation of α-synuclein (α-syn) in the brain is a core feature of Parkinson disease (PD) and leads to microglial activation, production of inflammatory cytokines and chemokines, T-cell infiltration, and neurodegeneration. Here, we have used both an in vivo mouse model induced by viral overexpression of α-syn as well as in vitro systems to study the role of the MHCII complex in α-syn-induced neuroinflammation and neurodegeneration. We find that in vivo, expression of full-length human α-syn causes striking induction of MHCII expression by microglia, while knock-out of MHCII prevents α-syn-induced microglial activation, antigen presentation, IgG deposition, and the degeneration of dopaminergic neurons. In vitro, treatment of microglia with aggregated α-syn leads to activation of antigen processing and presentation of antigen sufficient to drive CD4 T-cell proliferation and to trigger cytokine release. These results indicate a central role for microglial MHCII in the activation of both the innate and adaptive immune responses to α-syn in PD and suggest that the MHCII signaling complex may be a target of neuroprotective therapies for the disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
AAV2-SYN overexpression induces MHCII expression in vivo. A, α-syn (α-GFP, green) results in enhanced MHCII expression (α-MHCII, red) in the SNpc (α-TH, blue) 4 weeks post-transduction. Scale bar, 125 μm in the Merge part. AAV2-GFP and AAV2-SYN Zoom insets from white boxes shown. Scale bar, 75 μm. B, Quantification of MHCII staining in the SNpc of AAV2-GFP (control) and AAV2-SYN mice at 4 weeks. C, α-Syn (α-GFP, green) results in enhanced MHCII expression (α-MHCII, red) in the SNpc 12 weeks post-transduction in AAV2-SYN-injected animals. Confocal images were captured using a Leica TCS-SP5 laser-scanning confocal microscope. Images were processed using the Leica LASAF software, exported, and processed using Adobe Photoshop. For quantification of MHCII slides were observed using a Nikon Eclipse E800M fluorescent microscope. Coded slides were scored by using a numerical scale 0 (no staining) to 4 (most intense) by a single observer blind to the treatment paradigm. Data represent the median (n = 6/group) **p < 0.0043, Mann–Whitney test.
Figure 2.
Figure 2.
Genetic KO of MHCII attenuates AAV2-SYN-induced reactive microgliosis in vivo. A, α-Syn (α-GFP, green) results in enhanced CD11b+ microgliosis (α-CD11b, red) in the SNpc (α-TH, blue) 4 weeks post-transduction of WT mice but not MHCII KO mice. Scale bar, 125 μm. B, AAV2-GFP and AAV2-SYN Zoom insets from white boxes shown in A. Scale bar, 75 μm. C, Quantification of CD11b microgliosis in the SNpc of WT and MHCII KO mice 4 weeks post-transduction. D, α-Syn (α-GFP, green) results in enhanced CD11b+microgliosis (α-CD11b, red) in the SNpc (α-TH, blue) 12 weeks post-transduction of WT mice but not MHCII KO mice. Data represent the median (n = 6–8/group) *p < 0.05, **p < 0.01, Kruskal–Wallis test with Dunn's multiple-comparison post hoc test.
Figure 3.
Figure 3.
Genetic KO of MHCII attenuates AAV2-SYN-induced IgG deposition in vivo. A, Representative images of IgG deposition (α-IgG, red) on the ipsilateral side of α-syn overexpression (α-GFP, green) in WT versus MHCII KO mice. IgG deposition is markedly attenuated in virally transduced MHCII KO animals at 4 weeks (A) and 12 weeks (B).
Figure 4.
Figure 4.
Genetic KO of MHCII attenuates AAV2-SYN-induced neurodegeneration in vivo. Six months post-transduction TH-immunopositive neurons were quantified to determine observed neuroprotection. A, Representative images of the ipsilateral SNpc stained for TH. B, Genetic KO of MHCII attenuates AAV2-SYN-induced neuron loss. Neuron loss is reported as a percentage of contralateral side. n = 6–8/group one way ANOVA with Bonferroni selected comparison post hoc test. *p < 0.05.
Figure 5.
Figure 5.
Overexpression of AAV2-SYN in mouse SNpc results in the accumulation of high molecular weight α-syn species. Western blot analysis of α-syn of midbrain homogenates obtained from mice 4 weeks post-transduction into the right substantia nigra, using an antibody that is selective for human α-syn. There is an increase in high molecular weight α-syn species (≥50 kDa) is both the “whole” and Triton-soluble (“T-X-Sol”) fractions in homogenate fractions derived from right (R), infected ventral midbrain samples compared with that of noninfected left (L) control samples. There is also appearance of detectable soluble α-syn monomers (17 kDa). Insoluble high molecular weight forms of α-syn (“T-X-100-Insol” fraction) were observed only after AAV2-SYN treatment. Actin (42 kDa) was used to normalize for gel loading.
Figure 6.
Figure 6.
α-Syn regulates antigen processing and presentation in vitro. Primary microglia were treated with 500 nm aggregated α-syn or vehicle control (A) for 4 h (B) or overnight (C) before a 1 h pulse with DQ-Ovalbumin. Immunofluorescence was quantified from confocal images using ImageJ software (D). Four hour aggregated α-syn pretreatment resulted in an increase in antigen processing and presentation while overnight α-syn pretreatment decreased antigen processing and presentation. These effects were not observed with monomeric α-syn (E). One way ANOVA with Bonferroni multiple-comparisons post hoc test. ***p < 0.001, **p < 0.01 compared with control. Scale bar, 25 μm.
Figure 7.
Figure 7.
α-Syn-induces CD4 T-cell activation and proliferation in vitro. Primary microglia (previously treated with OVA323–339 and 500 nm α-syn for 6 h) and CD4 T-cell cocultures were pulsed with EdU for 1 h before flow cytometry analysis. A, No peptide control. Vehicle represented with solid line and shading, α-syn treatment represented with a dotted line. Primary microglia and CD4 T-cell cocultures revealed little or no EdU incorporation events. OVA peptide 1 μg/ml (B) and 10 μg/ml (C) treatment results in an increase in EdU+ events 60 h after coculture. Positive events were gated by live/dead, CD4, CD5, and EdU. D–I, α-syn pretreatment (500 nm) of primary microglia 6 h before T-cell coculture resulted in a statistically significant increase in pro-inflammatory cytokines and chemokines. All cytokine and chemokine expression levels were normalized to the level of vehicle-treated primary microglia and T-cell coculture. Student's t test (n = 3–4/group, representative of 2 independent experiments). D, 10 μg/ml OVA323–339 IL-1α *p < 0.0193. E, 10 μg/ml OVA323–339 IFNγ **p < 0.0087. F, 10 μg/ml OVA323–339 IL-1β ***p < 0.0009. G, 1 μg/ml OVA323–339 TNF **p < 0.0022. H, 10 μg/ml OVA323–339 TNF *p < 0.011. I, 10 μg/ml OVA323–339 IL-10 **p < 0.0021.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aloisi F, Serafini B, Adorini L. Glia-T-cell dialogue. J Neuroimmunol. 2000;107:111–117. doi: 10.1016/S0165-5728(00)00231-9. - DOI - PubMed
    1. Appel SH. Inflammation in Parkinson's disease: cause or consequence? Mov Disord. 2012;27:1075–1077. doi: 10.1002/mds.25111. - DOI - PubMed
    1. Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 2010;31:7–17. doi: 10.1016/j.it.2009.09.003. - DOI - PMC - PubMed
    1. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol. 1998;76:34–40. doi: 10.1046/j.1440-1711.1998.00709.x. - DOI - PubMed
    1. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the CSF of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. 1995;202:17–20. doi: 10.1016/0304-3940(95)12192-7. - DOI - PubMed

Publication types

Substances